Table Of Contents

1 Introduction	7
1.1 Industry Definition and Research Scope	7
1.1.1 Industry Definition	7
1.1.2 Research Scope	8
1.2 Research Methodology	11
1.2.1 Overview of Market Research Methodology	11
1.2.2 Market Assumption	12
1.2.3 Secondary Data	12
1.2.4 Primary Data	12
1.2.5 Data Filtration and Model Design	14
1.2.6 Market Size/Share Estimation	15
1.2.7 Research Limitations	16
1.3 Executive Summary	17
2 Market Overview and Dynamics	19
2.1 Market Size and Forecast	19
2.1.1 Impact of COVID-19 on World Economy	20
2.1.2 Impact of COVID-19 on the Market	23
2.2 Major Growth Drivers	25
2.3 Market Restraints and Challenges	30
2.4 Emerging Opportunities and Market Trends	33
2.5 Porter’s Fiver Forces Analysis	37
3 Segmentation of North America Market by Category	41
3.1 Market Overview by Category	41
3.2 Pharmaceutical Industry	43
3.3 Biopharmaceutical Industry	44
4 Segmentation of North America Market by Service Type	45
4.1 Market Overview by Service Type	45
4.2 Pharmaceutical Contract Manufacturing Organization (CMO)	47
4.2.1 Active Pharmaceutical Ingredients (API)	48
4.2.2 Finished Dosage Formulations (FDF)	49
4.2.3 Secondary Packaging	51
4.3 Pharmaceutical Contract Research Organization (CRO)	52
4.3.1 CRO for Pre-clinical Development	54
4.3.2 CRO for Phase I Trials	55
4.3.3 CRO for Phase II Trials	56
4.3.4 CRO for Phase III Trials	57
4.3.5 CRO for Phase IV Trials	58
4.3.6 Laboratory Services	59
4.3.7 Consulting Services	60
4.3.8 Data Management Services	61
5 Segmentation of North America Market by Therapeutic Application	62
5.1 Market Overview by Therapeutic Application	62
5.2 Infectious Diseases	64
5.3 Oncology	65
5.4 Metabolic Disorders	66
5.5 Cardiovascular Disorders	67
5.6 Central Nervous System	68
5.7 Pulmonary Disorders	69
5.8 Gastrointestinal Disorders	70
5.9 Other Therapeutic Applications	71
6 Segmentation of North America Market by End User	72
6.1 Market Overview by End User	72
6.2 Pharmaceutical & Biopharmaceutical Companies	74
6.3 Medical Device Companies	75
6.4 Academic Institutes	76
7 North America Market 2019-2030 by Country	77
7.1 Overview of North America Market	77
7.2 U.S.	80
7.3 Canada	84
7.4 Mexico	86
8 Competitive Landscape	88
8.1 Overview of Key Vendors	88
8.2 New Product Launch, Partnership, Investment, and M&A	92
8.3 Company Profiles	93
8.3.1 Company Profiles of CMO	93
Aenova Group	93
Baxter BioPharma Solutions	96
Boehringer Ingelheim	97
Catalent Inc.	98
Famar S.A.	99
Hospira, Inc.	100
Jubilant Life Sciences Ltd.	101
Lonza Group	102
Patheon Inc.	103
Pfizer CentreSource	104
Recipharm AB	105
Vetter Pharma International GmbH	106
8.3.2 Company Profiles of CRO	108
Charles River Laboratories	108
CMIC Co. Ltd	110
Covance Inc.	111
Hangzhou Tigermed Consulting Co Ltd	112
ICON Plc	113
IQVIA Holdings Inc.	114
LSK North America Pharma Service Co Ltd	115
Novotech Pty Ltd	116
PAREXEL International Corporation	117
Pharmaceutical Product Development LLC (PPD)	118
PRA Health Sciences Inc.	119
Quanticate Ltd	120
Samsung Bioepis Co. Ltd	121
SGS SA (SGS Life Sciences)	122
Syneos Health Inc.	123
WuXi AppTec Inc.	124
9 Investing in North America Market: Risk Assessment and Management	125
9.1 Risk Evaluation of North America Market	125
9.2 Critical Success Factors (CSFs)	128
Related Reports and Products	131

List Of Tables

Table 1.  Snapshot of North America Pharmaceutical CDMO Market in Balanced Perspective, 2019-2030	18
Table 2. Growth Rate of World Real GDP, 2017-2021	21
Table 3. World Top 10 Pharmaceutical Companies Based on Projected R&D Spending in 2026, $ bn	27
Table 4. Worldwide Total Number of Registered Clinical Trials	29
Table 5.  Main Product Trends and Market Opportunities in North America Pharmaceutical CDMO Market	33
Table 6. North America Pharmaceutical CDMO Market by Category, 2019-2030, $ bn	41
Table 7. North America Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn	45
Table 8. North America Pharmaceutical CDMO Market: CMO by Product, 2019-2030, $ bn	47
Table 9. North America Pharmaceutical CDMO Market: Active Pharmaceutical Ingredients (API) by Type, 2019-2030, $ bn	48
Table 10. North America Pharmaceutical CDMO Market: Finished Dosage Formulations (FDF) by Type, 2019-2030, $ bn	50
Table 11. North America Pharmaceutical CDMO Market: CRO by Service, 2019-2030, $ bn	53
Table 12. North America Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn	62
Table 13. North America Pharmaceutical CDMO Market by End User, 2019-2030, $ bn	72
Table 14. North America Pharmaceutical CDMO Market by Country, 2019-2030, $ bn	78
Table 15. U.S. Pharmaceutical CDMO Market by Category, 2019-2030, $ bn	82
Table 16. U.S. Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn	82
Table 17. U.S. Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn	82
Table 18. Canada Pharmaceutical CDMO Market by Category, 2019-2030, $ bn	85
Table 19. Canada Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn	85
Table 20. Canada Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn	85
Table 21. Mexico Pharmaceutical CDMO Market by Category, 2019-2030, $ bn	87
Table 22. Mexico Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn	87
Table 23. Mexico Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn	87
Table 24. Breakdown of North America CMO Market by Key Vendor, 2019, %	90
Table 25. Breakdown of North America CRO Market by Key Vendor, 2019, %	90
Table 26. Aenova Group: Company Snapshot	93
Table 27. Aenova Group: Business Segmentation	93
Table 28. Aenova Group: Product Portfolio	95
Table 29. Aenova Group: Revenue, 2016-2018, $ bn	95
Table 30. Aenova Group: Recent Developments	95
Table 31. Charles River Laboratories: Company Snapshot	108
Table 32. Charles River Laboratories: Business Segmentation	108
Table 33. Charles River Laboratories: Product Portfolio	109
Table 34. Charles River Laboratories: Revenue, 2016-2018, $ bn	109
Table 35. Charles River Laboratories: Recent Developments	109
Table 36.  Risk Evaluation for Investing in North America Market, 2019-2030	126
Table 37. Critical Success Factors and Key Takeaways	129

List Of Figures

Figure 1. Research Method Flow Chart	11
Figure 2. Breakdown of Primary Research	13
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation	15
Figure 4. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030	17
Figure 5. North America Pharmaceutical CDMO Market, 2019-2030, $ bn	19
Figure 6. Impact of COVID-19 on Business	23
Figure 7. Primary Drivers and Impact Factors of North America Pharmaceutical CDMO Market	25
Figure 8. Primary Restraints and Impact Factors of North America Pharmaceutical CDMO Market	30
Figure 9. Investment Opportunity Analysis	34
Figure 10. Porter’s Fiver Forces Analysis of North America Pharmaceutical CDMO Market	37
Figure 11. Breakdown of North America Pharmaceutical CDMO Market by Category, 2019-2030, % of Revenue	41
Figure 12. North America Addressable Market Cap in 2020-2030 by Category, Value ($ bn) and Share (%)	42
Figure 13. North America Pharmaceutical CDMO Market: Pharmaceutical Industry, 2019-2030, $ bn	43
Figure 14. North America Pharmaceutical CDMO Market: Biopharmaceutical Industry, 2019-2030, $ bn	44
Figure 15. Breakdown of North America Pharmaceutical CDMO Market by Service Type, 2019-2030, % of Sales Revenue	45
Figure 16. North America Addressable Market Cap in 2020-2030 by Service Type, Value ($ bn) and Share (%)	46
Figure 17. North America Pharmaceutical CDMO Market: Pharmaceutical Contract Manufacturing Organization (CMO), 2019-2030, $ bn	47
Figure 18. North America Pharmaceutical CDMO Market: Active Pharmaceutical Ingredients (API), 2019-2030, $ bn	48
Figure 19. North America Pharmaceutical CDMO Market: Finished Dosage Formulations (FDF), 2019-2030, $ bn	49
Figure 20. North America Pharmaceutical CDMO Market: Secondary Packaging, 2019-2030, $ bn	51
Figure 21. North America Pharmaceutical CDMO Market: Pharmaceutical Contract Research Organization (CRO), 2019-2030, $ bn	52
Figure 22. North America Pharmaceutical CDMO Market: CRO for Pre-clinical Development, 2019-2030, $ bn	54
Figure 23. North America Pharmaceutical CDMO Market: CRO for Phase I Trials, 2019-2030, $ bn	55
Figure 24. North America Pharmaceutical CDMO Market: CRO for Phase II Trials, 2019-2030, $ bn	56
Figure 25. North America Pharmaceutical CDMO Market: CRO for Phase III Trials, 2019-2030, $ bn	57
Figure 26. North America Pharmaceutical CDMO Market: CRO for Phase IV Trials, 2019-2030, $ bn	58
Figure 27. North America Pharmaceutical CDMO Market: Laboratory Services, 2019-2030, $ bn	59
Figure 28. North America Pharmaceutical CDMO Market: Consulting Services, 2019-2030, $ bn	60
Figure 29. North America Pharmaceutical CDMO Market: Data Management Services, 2019-2030, $ bn	61
Figure 30. Breakdown of North America Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, % of Sales Revenue	63
Figure 31. North America Addressable Market Cap in 2020-2030 by Therapeutic Application, Value ($ bn) and Share (%)	63
Figure 32. North America Pharmaceutical CDMO Market: Infectious Diseases, 2019-2030, $ bn	64
Figure 33. North America Pharmaceutical CDMO Market: Oncology, 2019-2030, $ bn	65
Figure 34. North America Pharmaceutical CDMO Market: Metabolic Disorders, 2019-2030, $ bn	66
Figure 35. North America Pharmaceutical CDMO Market: Cardiovascular Disorders, 2019-2030, $ bn	67
Figure 36. North America Pharmaceutical CDMO Market: Central Nervous System, 2019-2030, $ bn	68
Figure 37. North America Pharmaceutical CDMO Market: Pulmonary Disorders, 2019-2030, $ bn	69
Figure 38. North America Pharmaceutical CDMO Market: Gastrointestinal Disorders, 2019-2030, $ bn	70
Figure 39. North America Pharmaceutical CDMO Market: Other Therapeutic Applications, 2019-2030, $ bn	71
Figure 40. Breakdown of North America Pharmaceutical CDMO Market by End User, 2019-2030, % of Revenue	72
Figure 41. North America Addressable Market Cap in 2020-2030 by End User, Value ($ bn) and Share (%)	73
Figure 42. North America Pharmaceutical CDMO Market: Pharmaceutical & Biopharmaceutical Companies, 2019-2030, $ bn	74
Figure 43. North America Pharmaceutical CDMO Market: Medical Device Companies, 2019-2030, $ bn	75
Figure 44. North America Pharmaceutical CDMO Market: Academic Institutes, 2019-2030, $ bn	76
Figure 45. Breakdown of North America Pharmaceutical CDMO Market by Country, 2019 and 2030, % of Revenue	78
Figure 46. Contribution to North America 2020-2030 Cumulative Revenue by Country, Value ($ bn) and Share (%)	79
Figure 47. U.S. Pharmaceutical CDMO Market, 2019-2030, $ bn	81
Figure 48. Canada Pharmaceutical CDMO Market, 2019-2030, $ bn	84
Figure 49.  Pharmaceutical CDMO Market in Mexico, 2015-2030, $ bn	86
Figure 50. Growth Stage of North America Pharmaceutical CDMO Industry over the Forecast Period	88

Key Players (this may not be a complete list and extra companies can be added upon request): 
Company Profiles of CMO:
Aenova Group	
Baxter BioPharma Solutions	
Boehringer Ingelheim	
Catalent Inc.	
Famar S.A.	
Hospira, Inc.
Jubilant Life Sciences Ltd.	
Lonza Group	
Patheon Inc.	
Pfizer CentreSource	
Recipharm AB	
Vetter Pharma International GmbH	
8.3.2 Company Profiles of CRO:
Charles River Laboratories	
CMIC Co. Ltd	
Covance Inc.	
Hangzhou Tigermed Consulting Co Ltd	
ICON Plc	
IQVIA Holdings Inc.	
LSK Global Pharma Service Co Ltd	
Novotech Pty Ltd	
PAREXEL International Corporation	
Pharmaceutical Product Development LLC (PPD)	
PRA Health Sciences Inc.	
Quanticate Ltd	
Samsung Bioepis Co. Ltd	
SGS SA (SGS Life Sciences)	
Syneos Health Inc.	
WuXi AppTec Inc.